Treatment Outcomes of Olfactory Neuroblastoma: A Multicenter Study by the Korean Sinonasal Tumor and Skull Base Surgery Study Groupopen accessTreatment Outcomes of Olfactory Neuroblastoma: A Multicenter Study by the Korean Sinonasal Tumor and Skull Base Surgery Study Group
- Other Titles
- Treatment Outcomes of Olfactory Neuroblastoma: A Multicenter Study by the Korean Sinonasal Tumor and Skull Base Surgery Study Group
- Authors
- 홍상덕; 김동영; 박송이; 김지희; 허성재; 조성우; 원태빈; 조현진; 이동훈; 문수진; 박수경; 김용완
- Issue Date
- May-2024
- Publisher
- 대한이비인후과학회
- Keywords
- Keywords. Esthesioneuroblastoma; Neoadjuvant Therapy; Prognosis; Treatment Outcome
- Citation
- Clinical and Experimental Otorhinolaryngology, v.17, no.2, pp 137 - 146
- Pages
- 10
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Clinical and Experimental Otorhinolaryngology
- Volume
- 17
- Number
- 2
- Start Page
- 137
- End Page
- 146
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/70678
- DOI
- 10.21053/ceo.2023.00089
- ISSN
- 1976-8710
2005-0720
- Abstract
- Objectives. Due to the rarity of olfactory neuroblastoma (ONB), there is ongoing debate about optimal treatment strategies,especially for early-stage or locally advanced cases. Therefore, our study aimed to explore experiences from multiplecenters to identify factors that influence the oncological outcomes of ONB.
Methods. We retrospectively analyzed 195 ONB patients treated at nine tertiary hospitals in South Korea between Decem-ber 1992 and December 2019. Kaplan-Meier survival analysis was used to evaluate oncological outcomes, and a Coxproportional hazards regression model was employed to analyze prognostic factors for survival outcomes. Further-more, we conducted 1:1 nearest-neighbor matching to investigate differences in clinical outcomes according to theuse of neoadjuvant chemotherapy.
Results. In our cohort, the 5-year overall survival (OS) rate was 78.6%, and the 5-year disease-free survival (DFS) rate was62.4%. The Cox proportional hazards model revealed that the modified Kadish (mKadish) stage and Dulguerov Tstatus were significantly associated with DFS, while the mKadish stage and Hyams grade were identified as prognos-tic factors for OS. The subgroup analyses indicated a trend toward improved 5-year DFS with dural resection in mKadishA and B cases, even though the result was statistically insignificant. Induction chemotherapy did not provide a surviv-al benefit in this study after matching for the mKadish stage and nodal status.
Conclusion. Clinical staging and pathologic grading are important prognostic factors in ONB. Dural resection in mKadish Aand B did not show a significant survival benefit. Similarly, induction chemotherapy also did not show a survival ben-efit, even after stage matching.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.